Full Breakdown
Signal Ring Debuts as First Cuffless Blood-Pressure Smart Ring
7/18/2026, 12:11:34 AM
Launch Details and Core Claims
On July 16 2026, health-tech startup Vital Signals introduced the Signal Ring, a titanium smart ring that claims to measure systolic and diastolic blood pressure continuously from the finger. The device pairs with a companion app, offers “guided ‘Zen Mode’ episodic readings” and background monitoring, and is marketed as cuff-less, calibration-free. Pre-orders opened at $399 with a free sizing kit; the company says initial shipments will begin in October 2026. Vital Signals states the ring meets ISO 81060-2, the international accuracy standard for blood-pressure cuffs, and that its “proprietary high-speed sensor” captures blood-flow details that enable advanced algorithms to separate blood-pressure signals from other physiological changes.
Background & Health Context
According to the U.S. Centers for Disease Control and Prevention, 48.1 % of U.S. adults have hypertension, a major risk factor for stroke and heart disease. Traditional cuff-based monitors provide single, momentary readings and are often avoided because of discomfort. Existing wearables (e.g., Oura Ring, Apple Watch) can flag cardiovascular risk but do not deliver direct blood-pressure numbers, and cuff-based smartwatch models require periodic calibration.
Data & Statistics
- Clinical validation: a 451-person, multi-site study reported in the launch press release.
- Regulatory benchmark: compliance with ISO 81060-2.
- Hardware specs: titanium exterior, resin-lined interior, ~five-day battery life, US ring sizes 5 through 13.
- Pricing: $399 with no subscription fee.
Official Statements & Responses
Vital Signals emphasizes that its sensor “captures blood flow in greater detail, enabling advanced algorithms to separate blood pressure from other changing signals in the body.” Founder and CEO Tom Moss explained his personal motivation:
> “I had a life-threatening hypertensive event a few years ago, and what stayed with me wasn’t just how serious it was but also how little I understood afterward.”
Moss added that the company’s sole mission is to solve the “blood-pressure problem” and that the ring is intended to give users “a more convenient and reliable way to track and understand their blood pressure.” The company notes that the Signal Ring has not been reviewed or cleared by the FDA and is currently classified as an investigational wellness device.
Criticism & Opposition
Dr. Lindsey Rosman, assistant professor of medicine in the Division of Cardiology at the University of North Carolina School of Medicine, highlighted known limitations of photoplethysmography (PPG) sensors:
> “Motion can distort the signal, darker skin tones absorb more light and can produce a weaker signal, cold fingers or poor circulation alter blood flow independent of actual blood pressure, and irregular heartbeats can distort the waveform.”
She warned that inaccurate readings could cause “unnecessary worry or false assurance,” and called for more rigorous, publicly available testing. Rosman also noted that even clinical settings suffer from “white-coat hypertension,” underscoring the challenge of achieving reliable cuff-less measurements.
Conflicting Reports & Gaps
While Vital Signals cites ISO compliance, independent validation data have not been released, and the FDA has not granted clearance. Bloomberg reports that the company plans a separate medical-grade version for diagnostic use, but no timeline is provided. The lack of third-party performance data leaves a gap between the company’s claims and verifiable evidence.
Verbatim Quotes
- “Motion can distort the signal, darker skin tones absorb more light and can produce a weaker signal, cold fingers or poor circulation alter blood flow independent of actual blood pressure, and irregular heartbeats can distort the waveform,” — Dr. Lindsey Rosman, Assistant Professor of Medicine, University of North Carolina School of Medicine
- “Continuous data could reveal patterns a single reading misses, such as nighttime patterns, response to stress or medication, trends over weeks,” — Dr. Lindsey Rosman, Assistant Professor of Medicine, University of North Carolina School of Medicine
- “I had a life-threatening hypertensive event a few years ago, and what stayed with me wasn't just how serious it was but also how little I understood afterward,” — Tom Moss, Founder and CEO, Signal Ring
- “We needed a way to measure blood pressure from a wearable, not just measure changes from a baseline.” — Tom Moss, Founder and CEO, Signal Ring
- “This is our sole focus as a company,” — Tom Moss, Founder and CEO, Signal Ring
Why It Matters
If the Signal Ring can deliver accurate, continuous blood-pressure data, it could transform hypertension management by providing clinicians with richer trend information and encouraging more consistent self-monitoring. However, the current absence of FDA clearance and independent performance verification means that clinicians and consumers must weigh the promise against the risk of misleading readings. The device’s market entry therefore represents both a potential breakthrough in wearable health technology and a focal point for ongoing scrutiny of cuff-less blood-pressure measurement.
